Novartis's new heart failure drug to dominate with $1.9 billion global revenue by 2022, says GlobalData

21 June 2013

Following a launch scheduled for 2015 for the treatment of chronic heart failure (CHF), Swiss drug major Novartis’ (NOVN: VX) novel combination drug LCZ-696 will rapidly dominate the global CHF therapeutics sector and mark a drug development paradigm shift, says research and consulting firm GlobalData.

The firm’s latest report forecasts global sales of LCZ-696 to reach a massive $1.86 billion by 2022, with an estimated 15%-20% of all CHF patients across the USA and Europe treated with the drug by the end of the forecast period.

LCZ-696 expected to gain 55% share of US CHF market

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK